Elutia (ELUT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
The annual meeting is scheduled for June 11, 2026, with voting available online, by phone, or by mail for shareholders of record as of April 17, 2026.
Key proposals include director elections, auditor ratification, incentive plan amendment, executive compensation approval, and say-on-pay frequency.
The Board recommends voting for all proposals and a one-year frequency for say-on-pay votes.
Voting matters and shareholder proposals
Shareholders will vote on electing two Class III directors for terms expiring in 2029.
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026 is on the agenda.
Approval sought for the First Amendment to the 2020 Incentive Award Plan, increasing share authorization and extending plan duration.
Advisory votes on executive compensation and the frequency of future say-on-pay votes are included.
Shareholder proposals and director nominations for the 2027 meeting must comply with bylaw deadlines.
Board of directors and corporate governance
The Board consists of five directors divided into three classes, with regular evaluations and a mix of independent and management members.
Board committees include audit, compensation, and nominating/governance, each with defined charters and independent membership.
Corporate Governance Guidelines and a Code of Conduct are in place, with policies on insider trading and anti-hedging.
The Board separates the roles of CEO and Executive Chairman, both currently held by independent directors.
Latest events from Elutia
- Up to $26M in funding secured, improved margins, and strong surgeon demand for NXT-41x.ELUT
Q2 2026 - New drug-eluting biologic envelope gains traction with major partner and strong clinical benefits.ELUT
Planet MicroCap Showcase: VEGAS 2025 - EluPro's rapid adoption and a robust pipeline position the company for significant growth.ELUT
Cantor Global Healthcare Conference 2025 - Drug-eluting mesh targets high breast reconstruction infection rates, with launch expected next year.ELUT
Planet MicroCap Las Vegas 2026 - Antibiotic-eluting matrix targets high breast reconstruction infection rates in a $1.5B market.ELUT
16th Annual LD Micro Invitational Conference - Net sales up 6%, gross margin improved, and NXT-41/41x on track for 2026–2027 launch.ELUT
Q1 2026 - Votes will address director elections, auditor ratification, incentive plan, and executive pay.ELUT
Proxy filing - Q4 revenue up 16%, BioEnvelope sale drove debt repayment, and NXT-41x FDA process advanced.ELUT
Q4 2025 - FDA clearance for EluPro and improved margins offset by a $28.2M net loss and going concern risks.ELUT
Q2 2024